Fortis Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

Fortis Therapeutics General Information

Description

Developer of an immune-oncology drug designed to focus on the treatment of multiple myeloma and late-stage prostate cancer. The company prepares an antibody-drug conjugate for both adenocarcinoma and neuroendocrine cancer, enabling doctors to treat late-stage cancers effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fortis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Jul-2026 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series A) 29-Mar-2021 Completed Clinical Trials - Phase 1
1. Later Stage VC (Series A) 28-Sep-2016 $18M $18M Completed Startup
To view Fortis Therapeutics’s complete valuation and funding history, request access »

Fortis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Fortis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Fortis Therapeutics Patents

Fortis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022205348-A1 Combination therapy with for46 for cancer Pending 07-Jan-2021
AU-2022205348-A9 Combination therapy with for46 for cancer Pending 07-Jan-2021
CA-3204579-A1 Combination therapy with for46 for cancer Pending 07-Jan-2021
EP-4274661-A1 Combination therapy with for46 for cancer Pending 07-Jan-2021
EP-4274661-A4 Combination therapy with for46 for cancer Pending 07-Jan-2021 A61K47/6849
To view Fortis Therapeutics’s complete patent history, request access »

Fortis Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avalon Bioventures Venture Capital Minority
Fulcrum 2020 Other Minority
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
Prostate Cancer Foundation Not-For-Profit Venture Capital Minority
UCSF Innovation Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Fortis Therapeutics FAQs

  • When was Fortis Therapeutics founded?

    Fortis Therapeutics was founded in 2010.

  • Where is Fortis Therapeutics headquartered?

    Fortis Therapeutics is headquartered in La Jolla, CA.

  • What industry is Fortis Therapeutics in?

    Fortis Therapeutics’s primary industry is Drug Discovery.

  • Is Fortis Therapeutics a private or public company?

    Fortis Therapeutics is a Private company.

  • What is Fortis Therapeutics’s current revenue?

    The current revenue for Fortis Therapeutics is .

  • How much funding has Fortis Therapeutics raised over time?

    Fortis Therapeutics has raised $58M.

  • Who are Fortis Therapeutics’s investors?

    Avalon Bioventures, Fulcrum 2020, Myeloma Investment Fund, Prostate Cancer Foundation, and UCSF Innovation Ventures are 5 of 8 investors who have invested in Fortis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process